May 06, 2026
Something unprecedented just happened in Washington D.C…
FEATURED: Eli Lilly’s Numbers Are Exceptional Sponsored
Editor’s Note: Please read the following note from 60-year Wall Street veteran Marc Chaikin, who explains what Fed Chair Powell’s recent emergency meeting – called in response to a major AI lab breakthrough – could mean for your wealth.
Dear Reader,
Something unprecedented just happened in Washington D.C…
And the ripple effects could hit your money in a major way.
Treasury Secretary Scott Bessent and Fed Chair Jerome Powell recently summoned the CEOs of America’s biggest banks to an emergency meeting.
Why?
That’s why the U.S. government is rushing to deploy this technology across every major federal agency…
And why every major bank on the planet is now racing to get their hands on it.
JPMorgan is already in. So is Bank of America.
Goldman Sachs is even setting it to work on their most complex, back-office operations.
In other words, the U.S. government and the most powerful financial institutions in the world are begging one private AI lab for access to their technology.
And right now, there’s still a little-known way to claim a backdoor stake in this private firm for less than $40 – before what could be the biggest IPO of the year.
But please don’t delay. This profit window closes on June 16.
Regards,
Marc Chaikin
Founder, Chaikin Analytics
P.S. My award-winning system turned BULLISH on every member of the Magnificent Seven before they soared spectacularly…
Like Tesla in 2017 before it soared as much as 2,915%…
And Nvidia in 2014 before it soared as much as 55,000%.
Now it’s flashing BULLISH on a little-known “pre-IPO backdoor” into the most sought-after private AI firm in the world.
Best part of all? It trades for less than $40 a share.
Click here to see why I recommend swinging into action before June 16.
FEATURED
Eli Lilly’s Numbers Are Exceptional
Eli Lilly and Company (LLY) entered 2026 as one of the most watched large-cap equities on the planet – and the first four months have done nothing to quiet the conversation. After a significant pullback from its all-time high of $1,133.95 that took shares down toward the low-$600s earlier this year, LLY has staged a forceful recovery. As of May 6, 2026, the stock is trading near $988, powered by a Q1 earnings report that wasn’t just good – it was the kind of print that resets the analytical conversation entirely.
The Macro Backdrop: A Different Picture Than Earlier This Year
The macro environment has shifted meaningfully from the first-quarter pressure that drove high-multiple healthcare names lower. The Federal Reserve held the federal funds rate steady at 3.5% to 3.75% at its April 28–29 FOMC meeting – the third consecutive hold – following a series of rate cuts executed in late 2025. The 10-year Treasury yield is hovering near 4.39% to 4.44%, down from the more elevated levels that compressed growth multiples earlier in the year. That’s still not zero, but it’s a meaningfully different backdrop than what was pressuring the stock in Q1.
The Fed meeting itself was notable for internal friction – the April decision saw four dissenting votes, the most since 1992, with debate centering on whether additional rate increases might be warranted if inflation data deteriorates further. Middle East tensions have introduced an energy price wildcard that is keeping the Fed cautious. That uncertainty hasn’t disappeared, but market participants appear to have largely priced it in. For now, growth-oriented healthcare names are getting their footing back. Sponsored
Massive 512,000-Line Data Leak Exposes Shocking AI Breakthrough
60-year Wall Street veteran and financial technology pioneer Marc Chaikin recently reviewed a massive data leak inside one of the world’s biggest AI labs. He discovered a hidden mechanism in the code that could create extraordinary wealth for savvy investors – and inflict grave financial hardships on everyone else.
Click here for the full story.
Q1 2026 Results: The Numbers Are Hard to Argue With
Lilly reported Q1 2026 results on April 30, and the print was exceptional by almost any measure. Total revenue came in at $19.8 billion, up 56% year-over-year, driven by volume growth that outpaced even the most optimistic sell-side models. Adjusted EPS hit $8.55, against a consensus expectation of $6.66. Shares rose more than 10% in afternoon trading the day of the release.
- Mounjaro global revenue reached $8.66 billion in the quarter, more than doubling year-over-year. U.S. revenue was $4.2 billion (+59%), with international contributing $4.4 billion – up from just $1.2 billion in Q1 2025, driven by expansion into Europe, China, and Brazil.
- Zepbound U.S. revenue hit $4.16 billion, up 80% from the year-earlier period, beating analyst estimates of $4.04 billion. Volume surged even as realized prices declined on lower cash-pay pricing.
- Combined Mounjaro and Zepbound revenue totaled $12.8 billion for the quarter – a franchise that, annualized, would rank among the largest revenue-generating product lines in pharmaceutical history.
- Gross margin came in at approximately 81.9% on a reported basis, slightly lower year-over-year due to pricing pressure, but still exceptional in absolute terms and consistent with Lilly’s premium profile.
- Lilly holds 60.1% share of the U.S. obesity and diabetes GLP-1 market, versus Novo Nordisk’s 39.4%, according to the company’s own earnings presentation.
Following the beat, Lilly raised its full-year 2026 revenue guidance to $82 billion to $85 billion, up $2 billion from the prior range. Full-year adjusted EPS guidance was lifted to $35.50 to $37.00, from $33.50 to $35.00. International expansion – particularly in markets where patients are paying out of pocket across Europe, China, and Brazil – is now hitting stride and represents a material new growth driver that wasn’t a significant contributor twelve months ago.
Foundayo: The Oral GLP-1 Launch Changes the Narrative
One of the biggest structural developments in the Lilly story is no longer a future catalyst – it’s already happening. The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the only GLP-1 pill approved for weight loss that can be taken any time of day without food or water restrictions. Retail pharmacy availability began April 9. More than 20,000 people started taking Foundayo in the first few weeks after launch, and commercial copays were structured as low as $25 per month for insured patients.
Slight tangent, but it matters: Foundayo is a small molecule, which means it doesn’t require refrigeration, complex administration, or the cold-chain infrastructure that has constrained injectable GLP-1 distribution globally. CEO Dave Ricks has been explicit that Foundayo is the vehicle for scaling Lilly’s reach to markets where Zepbound logistics are prohibitive. That’s not a two-quarter story – it’s a multi-year expansion opportunity that is only beginning to show up in the data.
Foundayo is also not as potent as Zepbound. Clinical trials showed average weight loss of approximately 12.4% at the highest dose, versus the 20%-plus body weight reduction tirzepatide has demonstrated. Novo Nordisk’s oral Wegovy showed 16.6% in its trial. That efficacy gap is real and will matter to some patients and prescribers. Lilly’s argument is that convenience and accessibility expand the total addressable population more than they cannibalize the existing injectable market – and early prescription data is being watched closely to validate or challenge that thesis.
Valuation After the Recovery
At $988, the valuation conversation is different than it was when the stock was in the low-$700s. The multiple has reexpanded.
- Forward price-to-earnings at current levels: approximately 27 to 28 times 2026 guidance midpoint of $36.25 in adjusted EPS. That is a meaningful compression from the peak multiple near 55 times, but also a significant rerating from the oversold lows.
- The 52-week range spans from a low of $623.78 to a high of $1,133.95. At $988, the stock is trading approximately 13% below its 52-week high and roughly 58% above its 52-week low – a recovery that reflects how severely the market had discounted the fundamental trajectory.
- At current prices and guidance, the revenue multiple on 2026 estimates sits near 11 to 12 times – elevated relative to traditional pharma, but more defensible given the 56% growth rate posted in Q1 and the scale of the pipeline.
- Nineteen analysts maintain a Buy consensus rating with an average 12-month price target near $1,204, implying approximately 21% upside from current levels.
SponsoredSpaceX IPO 2026: What Investors Need to Know Now
SpaceX is still private, but credible reports and rising valuations suggest momentum may be building. If a filing happens, markets could move quickly. This Special Reportbreaks down what is confirmed, what is not, and the signals investors are watching closely right now.
The bear argument is not that Lilly is operationally broken – it clearly isn’t. The concern is that a 28-times forward multiple on a pharmaceutical company still prices in a significant growth premium, and any stumble in prescription trends, formulary dynamics, or pipeline execution gets amplified at that valuation. The Foundayo liver safety questions circulating in some analyst notes are worth monitoring, even if they aren’t yet material. At this price, there is less margin for error than there was at $650.
Pipeline Depth: Beyond the GLP-1 Conversation
Serious analysis of Lilly’s investment case can’t stop at tirzepatide and Foundayo. The pipeline carries multiple assets with commercial potential that are not yet fully reflected in base-case models.
- Kisunla (donanemab) for Alzheimer’s disease is now established in the market as the only amyloid-targeting therapy with evidence supporting stopping treatment once plaques are removed. Uptake is building as diagnostic infrastructure for early-stage Alzheimer’s expands. European launches are expected to begin contributing to growth through 2026.
- Ebglyss (lebrikizumab) for atopic dermatitis reported four-year durability data in March 2026 showing sustained disease control in the majority of patients, and positive Phase 3 results in pediatric patients were also reported – a potential label expansion into a new population.
- Retatrutide, a triple GIP/GLP-1/glucagon agonist in Phase 3, reported positive topline results in type 2 diabetes in March 2026, with up to 16.8% weight loss at 40 weeks. If the obesity Phase 3 program confirms what earlier data suggested, retatrutide could represent the next step-change in metabolic disease treatment beyond tirzepatide.
- Foundayo itself is in Phase 3 trials for type 2 diabetes, with Lilly planning to file for that indication before the end of Q2 2026. An expanded label would materially broaden the addressable patient population.
- Lilly completed four acquisitions in Q1 2026 alone – Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics – reflecting management’s active posture toward augmenting the internal pipeline across oncology, neuroscience, and rare disease.
Technical Structure: Where the Stock Stands
From a technical standpoint, LLY’s post-earnings recovery has been sharp. The stock broke down significantly from its 2024–2025 highs, traded into the low-$600s during the worst of the Q1 macro pressure, and has now staged a recovery that has brought it back toward the $1,000 level. That is not a small move – it reflects a fundamental re-anchoring of expectations following a quarter that exceeded even the more constructive sell-side models.
Near-term resistance sits at the psychologically significant $1,000 level, and more meaningfully at $1,050 to $1,100, which corresponds to the zone where the 2025 breakdown accelerated. A sustained reclaim of $1,000 on volume would be a structural positive. On the downside, support is now being rebuilt around $940 to $960, with a more significant level near $880 to $900 where volume accumulated during the recovery phase. The all-time high of $1,133.95, set in late 2025, remains the longer-term reclaim target for any structural bull thesis.
Options implied volatility has remained elevated relative to historical norms, which means the cost of defined-risk structures is higher than in calmer periods – but it also means the market is still pricing in meaningful uncertainty around near-term outcomes. That is worth accounting for in position sizing regardless of directional conviction.
Scenario Modeling From Here
Bull Case
Foundayo prescription volumes ramp meaningfully through Q2 and Q3, international Mounjaro penetration continues to accelerate, and retatrutide Phase 3 obesity data confirms the weight loss profile suggested by earlier trials. In that environment, shares could retest the $1,100 to $1,133 range and potentially challenge prior highs into year-end as analysts revise 2027 estimates upward. A Medicare GLP-1 Bridge program launching by July 1, 2026 – which CMS has confirmed, capping out-of-pocket costs at $50 per month for seniors – adds a structural demand catalyst that hasn’t yet shown up in prescription data.
Base Case
Revenue growth continues at the high end of guidance, Foundayo ramps gradually as payer coverage expands, and the stock consolidates in the $940 to $1,050 range through the summer as investors assess competitive dynamics between oral GLP-1 products. Valuation stabilizes around 26 to 28 times forward earnings, and shares grind modestly higher through the second half of 2026 as additional pipeline data points arrive.
Bear Case
Foundayo faces formulary access challenges or the liver safety questions cited in some analyst notes prove to be more than noise, Novo’s oral Wegovy erodes Lilly’s market share faster than expected, or macro conditions deteriorate on energy price shocks tied to Middle East instability. A sustained move below $880 would suggest the recovery has stalled and would open a path toward retesting the $800 area. That scenario requires multiple things going wrong simultaneously – but it is not zero probability given current geopolitical uncertainty.
Active Trader Framework
The dynamics here have shifted from the deep-value, oversold entry setup that existed when the stock was in the $650 to $720 range. At $988, traders are working with a stock that has already made a large move and is now approaching meaningful resistance. That changes the risk-reward calculus.
Key levels: $1,000 is the near-term psychological and technical pivot. A clean break and hold above $1,000 on volume opens the path toward $1,050 to $1,100. Failure to reclaim $1,000 after multiple attempts would set up a consolidation range with downside risk back toward $940. Prescription data releases, any updates on Foundayo’s formulary coverage trajectory, and the next Fed meeting will be the primary catalysts for directional movement in the weeks ahead.
Risk management discipline remains essential. A stock that moves 10% in a single session on earnings – which LLY just did – has a volatility profile that demands appropriate position sizing regardless of conviction level. The fundamental case is strong. That doesn’t mean the path higher is linear.
Lilly at $988 is a different conversation than Lilly at $715 – the valuation has reexpanded, the easy money from the oversold recovery has largely been made, and the next leg of the thesis depends on execution across a broader set of products than just Mounjaro and Zepbound. The pipeline is deep, the franchise momentum is real, and management has been consistent in its ability to deliver. But at this price, the margin for error is narrower. That’s where the work actually begins.
For informational and educational purposes only. Not investment advice. Trading involves risk, including loss of principal.
This content is for informational purposes only and should not be considered financial advice. Investing involves risk.
The Cheap Investor is a publication of Investing Media Solutions, LLC.
To view our full policies: Disclaimer | Privacy Policy | Terms & Conditions
Update your email preferences or unsubscribe here
© 2026 The Cheap Investor
203 N La Salle Suite 2100
Chicago , Illinois 60601, United StatesPowered by beehiivTerms of Service
RJ Hamster 